Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

NCT04956640 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

540

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung
Colorectal Neoplasms
Endometrial Neoplasms
Ovarian Neoplasms
Pancreatic Neoplasms
Biliary Tract Neoplasms

Interventions

DRUG: LY3537982
DRUG: Pembrolizumab
DRUG: Cetuximab
DRUG: Pemetrexed
DRUG: Cisplatin
DRUG: Carboplatin

Sponsor

Eli Lilly and Company

Collaborators

[object Object]